Literature DB >> 1783429

Re-organization of the immunoglobulin kappa gene on both alleles is not an obligatory prerequisite for Ig lambda gene expression in human cells.

H Abken1, C Bützler.   

Abstract

Re-arrangement and expression of the immunoglobulin (Ig) genes in B cells occurs under an ordered developmental control. The sequential model of Ig light chain exclusion predicts that only after non-productive re-organization or deletion of both Ig kappa alleles would re-arrangement of Ig lambda gene segments occur. To prove this model, we asked whether expression of Ig lambda light chains is always associated with rearrangement and/or deletion of both Ig kappa alleles in human cells. Therefore, we established human diploid B-cell clones in vitro that produce Ig lambda light chains. Southern blot analysis of the Ig kappa alleles revealed that three Ig lambda expressing cell lines (out of six Ig lambda+ cell lines tested) harbour one Ig kappa allele in germline configuration. Furthermore, a 1.5 kb RNA derived from the germline Ig kappa locus was detected by Northern blot hybridizations. The results implicate that the mechanism of Ig light chain exclusion is not precisely sequential and that it does not necessarily need re-arrangement or deletion of both Ig kappa alleles as a prerequisite for Ig lambda light chain expression in human cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783429      PMCID: PMC1384784     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  Novel recombinations of the IG kappa-locus that result in allelic exclusion.

Authors:  R M Feddersen; D J Martin; B G Van Ness
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

2.  Silencing of the expression of the immunoglobulin kappa gene in non-B cells.

Authors:  J W Pierce; A M Gifford; D Baltimore
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

3.  Identification of a germ line transcript from the unrearranged kappa gene in human B cells.

Authors:  D J Martin; B G Van Ness
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

4.  Frequent lambda light chain gene rearrangement and expression in a Ly-1 B lymphoma with a productive kappa chain allele.

Authors:  R R Hardy; J L Dangl; K Hayakawa; G Jager; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Fatal Hodgkin and non-Hodgkin lymphoma associated with persistent Epstein-Barr virus in four brothers.

Authors:  R Donhuijsen-Ant; H Abken; G Bornkamm; K Donhuijsen; H Grosse-Wilde; D Neumann-Haefelin; M Westerhausen; H Wiegand
Journal:  Ann Intern Med       Date:  1988-12-15       Impact factor: 25.391

6.  Murine lambda gene rearrangements: the stochastic model prevails over the ordered model.

Authors:  B Nadel; P A Cazenave; P Sanchez
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

7.  Ig lambda-producing B cells do not show feedback inhibition of gene rearrangement.

Authors:  K A Gollahon; J Hagman; R L Brinster; U Storb
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

8.  A uniform deleting element mediates the loss of kappa genes in human B cells.

Authors:  K A Siminovitch; A Bakhshi; P Goldman; S J Korsmeyer
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

9.  The kappa-deleting element. Germline and rearranged, duplicated and dispersed forms.

Authors:  W B Graninger; P L Goldman; C C Morton; S J O'Brien; S J Korsmeyer
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  Activation of V kappa gene rearrangement in pre-B cells follows the expression of membrane-bound immunoglobulin heavy chains.

Authors:  M Reth; E Petrac; P Wiese; L Lobel; F W Alt
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  1 in total

1.  A human immunoglobulin lambda locus is similarly well expressed in mice and humans.

Authors:  A V Popov; X Zou; J Xian; I C Nicholson; M Brüggemann
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.